Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or Without Diabetes?

Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or Without Diabetes? Curr Vasc Pharmacol. 2016 Sep 9; Authors: Athyros VG, Katsiki N, Karagiannis A PMID: 27633289 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/27633289?dopt=Abstract

Source: Current Vascular Pharmacology - September 8, 2016 Category: Drugs & Pharmacology Authors: Athyros VG, Katsiki N, Karagiannis A Tags: Curr Vasc Pharmacol Source Type: research

More News: Alcoholism | Diabetes | Drugs & Pharmacology | Endocrinology | SGLT2 Inhibitors